CEVEC offers a comprehensive portfolio of products and know-how. On the one hand we serve the global research community and on the other BioTech and Pharmaceutical Companies, who are interested in highest quality pharmaceuticals and the best technology for expression of their proteins.
We invest heavily in research and development and are an innovative creator and in-licensor of intellectual property. Our strong patent portfolio and further patent applications and our CAP and CAP-T Technologies are available for licensing and commercial use.

We believe that partnering offers new opportunities!

No matter if you are a current license holder, a developing company or an innovative research organization. We have license partners in the US, Europe and in several major markets of Asia Pacific.
CAP and CAP-T Technologies are used for the production of a wide range of proteins. Our proprietary expression technologies enable the discovery, development and production of vaccines, antibodies and therapeutic proteins.

CEVEC welcomes every new partner who is looking for a new and innovative human cell expression technology for its drug discovery and product development pipeline. We also look for strategic alliances for the marketing and sales of CEVEC´s own bio-better products. Partnering with other companies is of strategic importance to us.

If you want to partner with us or if you are looking for more information about our license holders and/or partners please contact us at:

GenIbet is a biopharmaceutical CMO (Contract Manufacturing Organization) offering highly specialized microbial, cell culture and viral propagation process development and cGMP manufacturing services to research groups, biotech and pharma companies. This, combined with in-house fill and finish capabilities, gives their clients the opportunity to go from bench to clinic in one facility. GenIbet’s core activity is the manufacture and supply of materials for use in early stage drug development, pre-clinical studies and cGMP manufacturing from Phase I to Phase III clinical trials.

SIRION Biotech was founded in Munich in 2006 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 300 single projects with more than 100 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies.

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products.  With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J.

InVivo is a leading contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins.
Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over ten years experience in mammalian cell culture and protein production. As a trusted provider of cost-effective outsourcing solutions, InVivo has worked with a large number of satisfied clients. Companies of all sizes, including small university spin-offs, major research institutes, and biopharmaceutical companies, have taken advantage of their expertise as an independent contract manufacturer.

The company provides a full range of development and manufacturing services to its customers, underpinned by excellent quality and a transparent customer experience.
Vibalogics is a privately owned contract development and manufacturing organisation (CDMO) offering services for companies committed to developing therapeutic and prophylactic vaccines and biological products. With a specific focus on viruses, live bacteria and aseptic processing, Vibalogics works in full compliance with international GMP standards in a BSL-2 classified state of the art facility in Germany.
With a modern facility and the basis for their operation built around provision of all activities for clinical drug development from feasibility assessment to product release, Vibalogics is perfectly positioned to manufacture your drug for the clinic.

For more than thirteen years, CCS has been supporting research departments of pharmaceutical and biotechnology companies with custom made functionally validated cell based reagents. CCS is one of the leading suppliers of recombinant cell lines, assay-ready frozen cells, qualified membranes, and proteins for high-throughput screening. Major pharmaceutical companies all over Europe and the USA rely on the custom products and services of CCS.

Paragon is a Contract Research & GMP Manufacturing Organization (CMO) delivering research, development and manufacturing services. Paragon's focus is biopharmaceuticals, including recombinant proteins, viral vectors, vaccines, VLPs, bacteriophage and stem cells. Their  clients include pharmaceutical companies, biotechnology companies and federal agencies.